ANNUAL OUT-OF-POCKET CAPS AND EQUITY-DRIVEN PATIENT COST-SHARING ACROSS EUROPEAN HEALTHCARE SYSTEMS: A 30-COUNTRY COMPARATIVE ANALYSIS
Author(s)
Krzysztof Nojszewski, MD1, Kinga Kocmierowska - Bobryk, MSc2, Anna Radziwilska-Muc, MBA3, Wojciech Nowak, MA, EMBA4, Grzegorz Obrzut5, Magdalena Marzec6.
1Novartis Poland, Warsaw, Poland, 2NOVARTIS, Warsaw, Poland, 3sanofi, Warszawa, Poland, 4Novartis Pharma, Basel, Switzerland, 5Certara EVA, Kraków, Poland, 6Certara, Poland.
1Novartis Poland, Warsaw, Poland, 2NOVARTIS, Warsaw, Poland, 3sanofi, Warszawa, Poland, 4Novartis Pharma, Basel, Switzerland, 5Certara EVA, Kraków, Poland, 6Certara, Poland.
OBJECTIVES: To benchmark annual patient out-of-pocket (OOP) caps and equity-driven cost-sharing exemptions across 30 European countries (EU-27, UK, Switzerland, Norway) and assess how cap design (fixed-amount, income-proportional, progressive) influences financial protection for vulnerable populations: chronically ill, children, low-income households, and pensioners.
METHODS: Cap structures and exemption rules were extracted from official payer and health-ministry sources and the Certara Market Access RADAR database. OOP cap thresholds were standardized to euros (€) and stratified by type. Findings were complemented by a PubMed review and semi-structured interviews with 12 HTA and market access experts across 13 countries, using cluster framework.
RESULTS: Sixteen of 30 countries have implemented annual OOP caps on patient cost-sharing; Portugal has none. Three archetypes emerged. (a) Fixed-amount caps: Czech Republic (CZK 5,000 / €206.75; CZK 1,000 / €41.35 children/seniors 65+; CZK 500 / €20.68 for 70+), Norway (NOK 3,278 / €298.3), Finland (€633), Latvia (€570), Denmark (DKK 4,850 / €648.86). (b) Income-proportional caps: Germany (2% of household income; 1% for chronically ill), Belgium (income-banded maximum-à-facturer), Spain (income-stratified monthly limits). (c) Progressive tiered systems: Sweden (full price to SEK 2,000 / €182.08; cap at SEK 3,800 / €342.95), Finland (full price to €70 then tiered discounts), Denmark, Estonia (from 2025: 50% rebate above €100, 90% above €300). Child-specific exemptions exist in Sweden, Czech Republic, and Cyprus; the Netherlands combines a €385 deductible with a separate €250 pharmaceutical cap; Slovakia uses quarterly caps (pensioners €45; disabled €30).
CONCLUSIONS: European systems converge toward annual caps but diverge in equity sensitivity. Income-proportional and progressive tiered models offer stronger protection for low-income and chronically ill patients than fixed nominal caps, which can be regressive in real terms. Hybrid designs and exemptions for vulnerable groups are most equity protective. Harmonization toward income-adjusted progressive caps could materially reduce financial barriers to medicines across Europe.
METHODS: Cap structures and exemption rules were extracted from official payer and health-ministry sources and the Certara Market Access RADAR database. OOP cap thresholds were standardized to euros (€) and stratified by type. Findings were complemented by a PubMed review and semi-structured interviews with 12 HTA and market access experts across 13 countries, using cluster framework.
RESULTS: Sixteen of 30 countries have implemented annual OOP caps on patient cost-sharing; Portugal has none. Three archetypes emerged. (a) Fixed-amount caps: Czech Republic (CZK 5,000 / €206.75; CZK 1,000 / €41.35 children/seniors 65+; CZK 500 / €20.68 for 70+), Norway (NOK 3,278 / €298.3), Finland (€633), Latvia (€570), Denmark (DKK 4,850 / €648.86). (b) Income-proportional caps: Germany (2% of household income; 1% for chronically ill), Belgium (income-banded maximum-à-facturer), Spain (income-stratified monthly limits). (c) Progressive tiered systems: Sweden (full price to SEK 2,000 / €182.08; cap at SEK 3,800 / €342.95), Finland (full price to €70 then tiered discounts), Denmark, Estonia (from 2025: 50% rebate above €100, 90% above €300). Child-specific exemptions exist in Sweden, Czech Republic, and Cyprus; the Netherlands combines a €385 deductible with a separate €250 pharmaceutical cap; Slovakia uses quarterly caps (pensioners €45; disabled €30).
CONCLUSIONS: European systems converge toward annual caps but diverge in equity sensitivity. Income-proportional and progressive tiered models offer stronger protection for low-income and chronically ill patients than fixed nominal caps, which can be regressive in real terms. Hybrid designs and exemptions for vulnerable groups are most equity protective. Harmonization toward income-adjusted progressive caps could materially reduce financial barriers to medicines across Europe.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HPR40
Topic
Health Policy & Regulatory, Health Technology Assessment, Patient-Centered Research
Topic Subcategory
Health Disparities & Equity, Insurance Systems & National Health Care, Public Spending & National Health Expenditures, Reimbursement & Access Policy
Disease
No Additional Disease & Conditions/Specialized Treatment Areas